TORONTO, June 30, 2026 /CNW/ - Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced it is the first to receive Health Canada's approval for a generic equivalent of Wegovy® (semaglutide injection) for chronic weight management in adults.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
